« Back
Home /
EPO-alpha/Fc Chimera, Human

EPO-alpha/Fc Chimera, Human

Item no.	Z02907-1
Manufacturer	GenScript
Amount	1 mg
Quantity options	1 mg 10 ug
Category	Oncology Peptides & Proteins Recombinant Proteins Cell Biology Cell Status Proliferation By Organ Heart & Blood Cancer
Type	Proteins
Specific against	Human (Homo sapiens)
Purity	>98% by SDS-PAGE and HPLC analyses.
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	protein/Z02907-EPO-Fc_Human, Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients.Erythropoietin/Fc Chimera is a long-acting version of EPO.</td></tr><tr><th>M.W.</th><td colspan="7"> Recombinant Human EPO/Fc produced in CHO is a dimeric, glycosylated, polypeptide chain consisting of two mature human EPO molecules linked to the Fc portion of human IgG1. The Fc component contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 140 kDa in non-reducing SDS-PAGE.</td></tr><tr><th>Purity</th><td colspan="7"> >98% by SDS-PAGE and HPLC analyses.</td></tr><tr><th>Endotoxin Level</th><td colspan="7"> Less than 0.2EU/ug of rHuEPO-Fc a as determined by LAL method.</td></tr><tr><th>Specific Activity</th><td colspan="7"> Fully biologically active when compared to standard. The ED50 determined by a cell proliferation assay using human megakaryoblastic leukemia cells is less than 2 ng/ml, corresponding to a specific activity of >5.0 × 105 IU/mg.</td></tr><tr><th>Storage</th><td colspan="7"> This lyophilized preparation is stable at 2-8C, but should be kept at -20C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -70C. Avoid repeated freeze/thaw cycles.</td></tr><tr><th>Formulation</th><td colspan="7"> Lyophilized from a 0.2um filtered concentrated solution in PBS, pH 7.4.</td></tr><tr><th>Reconstitution</th><td colspan="7"> We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20C. Further dilutions should be made in appropriate buffered solutions.</td></tr>
Similar products	EPO-alpha/Fc
Available
Specificity	Fully biologically active when compared to standard. The ED50 determined by a cell proliferation assay using human megakaryoblastic leukemia cells is less than 2 ng/ml, corresponding to a specific activity of >5.0 x 105 IU/mg.
Country of Origin	USA
Storage Conditions	This lyophilized preparation is stable at 2-8C, but should be kept at -20C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -70C. Avoid repeated freeze/thaw cycles.
Molecular Weight	Recombinant Human EPO/Fc produced in CHO is a dimeric, glycosylated, polypeptide chain consisting of two mature human EPO molecules linked to the Fc portion of human IgG1. The Fc component contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 140 kDa in non-reducing SDS-PAGE.
Product Line	Cytokine, Chemokines & Growth Factors
Manufacturer - Specificity	Fully biologically active when compared to standard. The ED50 determined by a cell proliferation assay using human megakaryoblastic leukemia cells is less than 2 ng/ml, corresponding to a specific activity of >5.0 x 105 IU/mg.
Description	Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients.Erythropoietin/Fc Chimera is a long-acting version of EPO.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20C. Further dilutions should be made in appropriate buffered solutions.
Formulation	Lyophilized from a 0.2um filtered concentrated solution in PBS, pH 7.4.
Endotoxin Level	Less than 0.2EU/ug of rHuEPO-Fc a as determined by LAL method.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Z02907-1-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Delivery expected until 11/13/2025

Express Delivery: Save 1 days

Compare

Add to wishlist

Get an offer